Nabriva Therapeutics plc

NBRVF · OTC
Analyze with AI
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Activities
Net Income-$57,185-$49,450-$69,484-$82,764
Dep. & Amort.$217$637$820$770
Deferred Tax$0$0$2,757$0
Stock-Based Comp.$1,967$3,291$5,219$9,748
Change in WC$13,733-$14,857-$11,391-$195
Other Non-Cash$4,557$822$748$549
Operating Cash Flow-$36,711-$59,557-$71,331-$71,892
Investing Activities
PP&E Inv.-$211-$25-$113-$61
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.-$52-$56-$161$392
Investing Cash Flow-$263-$81-$274$331
Financing Activities
Debt Repay.-$2,921$0-$30,000$9,980
Stock Issued$2,123$27,911$53,460$20,138
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$2,649$38,455$3,464$25,957
Financing Cash Flow$1,851$66,366$26,924$56,075
Forex Effect-$174-$484-$140-$106
Net Chg. in Cash-$35,297$6,244-$44,821-$15,592
Supplemental Information
Beg. Cash$47,834$41,590$86,411$102,003
End Cash$12,537$47,834$41,590$86,411
Free Cash Flow-$36,922-$59,582-$71,444-$71,953